ClinVar Miner

Submissions for variant NM_001354604.2(MITF):c.997G>A (p.Glu333Lys)

gnomAD frequency: 0.00001  dbSNP: rs147682682
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Human Genetics, Inc, Center for Human Genetics, Inc RCV000659864 SCV000781746 uncertain significance Waardenburg syndrome type 2A 2016-11-01 criteria provided, single submitter clinical testing
Knight Diagnostic Laboratories, Oregon Health and Sciences University RCV001270110 SCV001448958 uncertain significance not provided 2019-04-04 criteria provided, single submitter clinical testing
GeneDx RCV001270110 SCV002562400 uncertain significance not provided 2024-12-06 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Labcorp Genetics (formerly Invitae), Labcorp RCV002530560 SCV003214371 uncertain significance Tietz syndrome; Waardenburg syndrome type 2A; Melanoma, cutaneous malignant, susceptibility to, 8 2024-10-28 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 226 of the MITF protein (p.Glu226Lys). This variant is present in population databases (rs147682682, gnomAD 0.002%). This missense change has been observed in individual(s) with clinical features of Waardenburg syndrome (internal data). ClinVar contains an entry for this variant (Variation ID: 547533). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MITF protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV004026048 SCV003542857 uncertain significance Hereditary cancer-predisposing syndrome 2024-03-28 criteria provided, single submitter clinical testing The c.676G>A (p.E226K) alteration is located in exon 7 (coding exon 7) of the MITF gene. This alteration results from a G to A substitution at nucleotide position 676, causing the glutamic acid (E) at amino acid position 226 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV004745542 SCV005353824 uncertain significance MITF-related disorder 2024-05-10 no assertion criteria provided clinical testing The MITF c.676G>A variant is predicted to result in the amino acid substitution p.Glu226Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0026% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.